Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2025-04-02 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Pending Release of Shares from Voluntary Escrow 2 pages 147.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited regarding the pending release of shares from voluntary escrow related to an acquisition transaction. It references ASX Listing Rule 3.10A and details the number of shares and release date. The document is an announcement about share release and does not contain financial statements, management discussion, or detailed financial data. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or investor presentation. It is also not a regulatory certification or legal proceeding update. The content fits best with a Regulatory Filing (RNS) as it is a general regulatory announcement about share escrow release, which does not fit other more specific categories.
2025-04-02 English
Pending Release of Shares from Voluntary Escrow 2 pages 148.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited regarding the pending release of shares from voluntary escrow related to an acquisition. It references compliance with ASX Listing Rule 3.10A and details the number of shares and release date. The document does not contain financial statements or detailed financial analysis but is a regulatory announcement about share release. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or management report. It is also not a voting result or capital change announcement but a notification about share escrow release. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-04-02 English
Application for quotation of securities - TLX 8 pages 25.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options exercised or convertible securities converted. The document includes specifics such as the number of securities, issue dates, and whether the securities are issued for cash or other considerations. It does not contain financial statements, management discussion, or earnings data. It is not a report but an official announcement related to capital changes and securities quotation. Therefore, the document fits the category of Share Issue/Capital Change (SHA).
2025-04-02 English
Notification of cessation of securities - TLX 4 pages 15.0KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of certain securities (Share Appreciation Rights) for Telix Pharmaceuticals Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. This type of announcement is a regulatory notification about changes in the company's securities, specifically cessation of securities rights, which aligns with a Major Shareholding Notification or similar capital structure update. However, since it is about cessation of securities and changes in issued capital, it fits best under the category of Share Issue/Capital Change (SHA). The document is not a full financial report, earnings release, or management report, but a formal announcement of capital changes.
2025-04-02 English
Pending Release of Shares from Voluntary Escrow 2 pages 151.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX release from Telix Pharmaceuticals Limited dated 2 April 2025. It announces the pending release of shares from voluntary escrow related to an acquisition transaction. The content focuses on share release details, references ASX Listing Rule 3.10A, and includes background information about the company and legal disclaimers. There are no financial statements, detailed financial performance data, or management discussion of results. The document is a regulatory announcement about share escrow release, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other more specific categories like capital changes or director dealings. The document length is moderate but the content is clearly an announcement rather than a full report or financial supplement.
2025-04-01 English
Change in substantial holding 70 pages 475.3KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 under the Corporations Act 2001, specifically a 'Notice of change of interests of substantial holder.' It details changes in voting power and relevant interests of a substantial shareholder, including names, dates, and share counts. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is substantive and not merely an announcement or certification, and it does not fit other categories such as financial reports or management information.
2025-04-01 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.